MAZE Maze Therapeutics, Inc. — earnings, filings & institutional moves

Price chart

Daily historical data with per-account defaults

Latest close

$24.27

Period return

-17.19 (-41.46%)

Volume

445.6K

2026-06-05O $25.47 H $25.68 L $23.61 C $24.27MA5 $24.86MA20 $25.57MA60 $30.24MA120 $36.97

6M · 124 barsYahoo Finance · USD2025-12-08 → 2026-06-05

Recent event timeline

Filings, earnings, research, and institutional changes — newest first

View all →

2026. 04. 14.LowBUY2 months ago
Truist Securities: Buy
US analyst rating / recommendation change.
2026. 04. 01.LowBUY2 months ago
JP Morgan: Overweight
US analyst rating / recommendation change.
2026. 03. 26.LowBUY2 months ago
BTIG: Buy
US analyst rating / recommendation change.

Recent earnings

Consensus vs. actual, and revenue trend

Earnings tab →

Research actions

Consensus PT $62.55 · 11 analysts

Research tab →

AI Brief (Premium)

Automated summary from public sources · not investment advice

Brief tab →

No AI brief generated yet. You can create one from the Brief tab.

Top institutions (13F)

Ranked by position value

Institutions tab →

Company info

Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease. The company also develops MZE001, an investigational oral small molecule inhibitor of muscle-specific glycogen synthase clinical program for the treatment of Pompe disease. It has a license agreement with Trace Neuroscience, Inc. to discovery research program targets UNC13A; the Shionogi & Co., Ltd to research, develop, manufacture, and commercialize MZE001; and Neurocrine Biosciences, Inc. to discover research program that targets ATXN2. The company was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.

Sector: Healthcare
Industry: Biotechnology
HQ: South San Francisco, CA, United States
Fiscal year end: —

2026. 03. 26.LowBUY2 months ago

HC Wainwright & Co.: Buy